Table of Contents

• Overview of LY3372689
• Mechanism of Action
• Current Clinical Trial
• Eligibility Criteria
• Drug Administration
• Potential Benefits

Overview of LY3372689

LY3372689 is a new investigational drug being developed by Eli Lilly and Company for the treatment of early symptomatic Alzheimer’s disease^[1]. This medication, also known by its chemical name N-[4-FLUORO-5-[[2S,4S)-2-METHYL-4-[(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHOXY]-1-PIPERIDINYL]METHYL]-2-THIAZOLYL-ACETAMIDE, is currently undergoing clinical trials to assess its safety, tolerability, and efficacy in patients with early-stage Alzheimer’s disease^[1].

Mechanism of Action

While the exact mechanism of action is not explicitly stated in the provided information, LY3372689 is being studied for its potential to slow down clinical progression in patients with early symptomatic Alzheimer’s disease who have moderate levels of tau pathology^[1]. Tau pathology refers to the abnormal accumulation of tau proteins in the brain, which is a characteristic feature of Alzheimer’s disease.

Current Clinical Trial

A Phase II clinical trial, identified as I9X-MC-MTAE, is currently underway to evaluate LY3372689^[1]. The main objective of this study is to assess the effect of LY3372689 compared to a placebo on clinical progression in participants with early symptomatic Alzheimer’s disease who have demonstrated the presence of moderate levels of tau pathology^[1].

The primary endpoint of the study is the change from baseline to the end timepoint in the Integrated Alzheimer’s Disease Rating Scale (iADRS)^[1]. This scale is a comprehensive measure used to assess cognitive and functional abilities in Alzheimer’s disease patients.

Eligibility Criteria

To participate in the clinical trial for LY3372689, patients must meet specific criteria. These include:

• Gradual and progressive change in memory function reported by participants or informants for 6 months or longer^[1]. This means that the patient or their caregiver has noticed a slow but steady decline in memory over at least half a year.
• A Mini-Mental State Examination (MMSE) score between 22 and 30 (inclusive) at baseline^[1]. The MMSE is a common test used to assess cognitive function, with scores in this range indicating mild cognitive impairment to normal cognition.
• A Clinical Dementia Rating (CDR) global score between 0.5 and 1.0 (inclusive), with a memory box score of 0.5 or higher^[1]. The CDR is another tool used to evaluate cognitive and functional performance, with these scores suggesting very mild to mild dementia.
• Meeting specific criteria on a 18F flortaucipir positron emission tomography (PET) scan^[1]. This advanced brain imaging technique is used to detect tau protein accumulation in the brain.
• Having a study partner who can provide informed consent to participate^[1]. This person, often a family member or close friend, helps provide information about the patient’s condition and assists with study procedures.

Exclusion criteria include having contraindications to MRI or PET scans, or known allergies to LY3372689, related compounds, or any components of the drug formulations^[1].

Drug Administration

LY3372689 is formulated as a tablet and is administered orally^[1]. The maximum treatment period in the current clinical trial is set at 200 weeks, which is approximately 3.8 years^[1]. Specific dosage information is not provided in the available data.

Potential Benefits

While it’s important to note that LY3372689 is still in the investigational stage, the drug shows promise for potentially slowing down the progression of early Alzheimer’s disease. If successful, it could offer a new treatment option for patients in the early stages of this devastating condition. However, as with all clinical trials, the full benefits and risks of the drug will only be known after the completion of rigorous testing and analysis^[1].